Search Results - immunooncology

3 Results Sort By:
Affinity and Functional Based Screening of T Cell Receptor Repertoire Using Nanovials (Case No. 2024-042)
Summary: Researchers in the Department of Bioengineering at UCLA have developed a hydrogel platform that measures single T cell secretions, aiding in the definition of T cell receptor repertoires for functional immunotherapy applications. Background: T cell immunotherapies, namely T cell receptor (TCR) therapies, have emerged as promising candidates...
Published: 9/20/2024   |   Inventor(s): Dino Di Carlo, Owen Witte, Doyeon Koo, Zhiyuan Mao
Keywords(s): Cancer Immunotherapy, CAR-T cell therapy, Flow Cytometry, hydrogel, Immunooncology, Immunotherapy, Peptide, single cell analysis, T Cell, T cell based therapy
Category(s): Diagnostic Markers > Immunology, Life Science Research Tools > Screening Libraries, Therapeutics > Immunology And Immunotherapy
Inhibition of BMI1 Eliminated Cancer Stem Cells and Activates Antitumor Immunity (UCLA Case No. 2020-858)
UCLA researchers in the Department of Dentistry discovered that targeting BMI1in head and neck squamous cell carcinoma (HNSCC) may be a viable immune checkpoint to inhibit metastatic tumor growth, and prevent tumor relapse through activation of cell-intrinsic immunity and purging cancer stem cells (CSCs). BACKGROUND: Cancer stem cells are cancer...
Published: 3/6/2024   |   Inventor(s): Cun-Yu Wang, Jia Lingfei
Keywords(s): Cancer stem cells, Epigenetics, Immunooncology, Oncology Immunotherapy, Tumor
Category(s): Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Gene Therapy And Editing
Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1
Abstract: Immune checkpoint inhibitors (e.g. CTLA-4, PD-L1) have recently shown significant promise in the treatment of cancer.  However, when used alone, these checkpoint inhibitors are limited by the absence or repression of immune cells within the targeted cancer.  For those cancers associated with these limited immune systems, there remains a need...
Published: 5/22/2024   |   Inventor(s): Joost Oppenheim, De Yang, Michael Bustin
Keywords(s): Alarmin, Checkpoint Inhibitor, CTLA-4, HMGN1, Immunooncology, Oppenheim, TLR4, TLR7/8
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics